Latest Mental Health News

Page 5 of 13
Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.
Ada Torres
Ada Torres
20 Apr 2026
Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.
Ada Torres
Ada Torres
14 Apr 2026
Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.
Ada Torres
Ada Torres
2 Apr 2026
Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.
Ada Torres
Ada Torres
2 Apr 2026
Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.
Ada Torres
Ada Torres
24 Mar 2026
Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.
Ada Torres
Ada Torres
19 Mar 2026
Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.
Ada Torres
Ada Torres
4 Mar 2026
Future Generation Global Limited reported a 50% drop in net profit for 2025 but maintained strong investment portfolio growth and declared a special fully franked dividend, while continuing its significant social impact contributions.
Claire Turing
Claire Turing
27 Feb 2026
Metals X Limited reported a robust 2025 financial year with revenue up 30% to $285 million, driven by higher tin prices despite a slight dip in production. The company is advancing its key growth project, Rentails, targeting a final investment decision in late 2026.
Maxwell Dee
Maxwell Dee
27 Feb 2026
Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.
Ada Torres
Ada Torres
26 Feb 2026
NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.
Sophie Babbage
Sophie Babbage
25 Feb 2026

Browse the archive

Full archive